3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
226
Lymphoma
221
Lymphoma, Non-Hodgkin
194
Leukemia, Lymphocytic, Chronic, B-Cell
175
Lymphoma, Large B-Cell, Diffuse
170
Lymphoma, Follicular
164
Lymphoma, B-Cell
108
Lymphoma, Mantle-Cell
102
Hodgkin Disease
99
Recurrence
94
Leukemia, Myeloid, Acute
94
Multiple Myeloma
89
Burkitt Lymphoma
86
Leukemia
76
Neoplasms
66
Hematologic Neoplasms
58
Lymphoma, B-Cell, Marginal Zone
56
Myelodysplastic Syndromes
52
Waldenstrom Macroglobulinemia
42
Lymphoma, T-Cell
42
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
37
Lymphoma, T-Cell, Peripheral
35
Lymphoma, T-Cell, Cutaneous
31
Leukemia, Biphenotypic, Acute
28
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
27
Leukemia, B-Cell
27
Mycosis Fungoides
25
Lymphoma, Large-Cell, Anaplastic
25
Sarcoma
24
Lymphoproliferative Disorders
20
Interventions
CLR1404
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Blood Protein Disorders
×
Lymphoid
×
90 days
×
Clear all
NCT07075185
2026-04-24
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1
Recruiting
70 enrolled
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled